Katherine A. Rybinski

585 total citations
23 papers, 464 citations indexed

About

Katherine A. Rybinski is a scholar working on Oncology, Molecular Biology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Katherine A. Rybinski has authored 23 papers receiving a total of 464 indexed citations (citations by other indexed papers that have themselves been cited), including 13 papers in Oncology, 6 papers in Molecular Biology and 6 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Katherine A. Rybinski's work include HER2/EGFR in Cancer Research (8 papers), Cancer Treatment and Pharmacology (4 papers) and Cancer-related Molecular Pathways (3 papers). Katherine A. Rybinski is often cited by papers focused on HER2/EGFR in Cancer Research (8 papers), Cancer Treatment and Pharmacology (4 papers) and Cancer-related Molecular Pathways (3 papers). Katherine A. Rybinski collaborates with scholars based in United States, Japan and Australia. Katherine A. Rybinski's co-authors include Luigi Grasso, Nicholas C. Nicolaides, Yuhong Zhou, Philip M. Sass, Brian Tomkowicz, Earl F. Albone, Brian Foley, Wolfgang Ebel, Eric Routhier and Shawn Fernando and has published in prestigious journals such as Proceedings of the National Academy of Sciences, Journal of Clinical Oncology and Cancer Research.

In The Last Decade

Katherine A. Rybinski

23 papers receiving 439 citations

Peers

Katherine A. Rybinski
Wendy Cooper United States
Bianca Sijmons Netherlands
Cécile Rouleau United States
Christel Herzog Germany
Terry Lipari United States
Z Zhu China
Hilda Tsai United States
Khashayar Lessan United Kingdom
Akinao Haba United States
Joëlle d'Anjou France
Wendy Cooper United States
Katherine A. Rybinski
Citations per year, relative to Katherine A. Rybinski Katherine A. Rybinski (= 1×) peers Wendy Cooper

Countries citing papers authored by Katherine A. Rybinski

Since Specialization
Citations

This map shows the geographic impact of Katherine A. Rybinski's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Katherine A. Rybinski with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Katherine A. Rybinski more than expected).

Fields of papers citing papers by Katherine A. Rybinski

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Katherine A. Rybinski. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Katherine A. Rybinski. The network helps show where Katherine A. Rybinski may publish in the future.

Co-authorship network of co-authors of Katherine A. Rybinski

This figure shows the co-authorship network connecting the top 25 collaborators of Katherine A. Rybinski. A scholar is included among the top collaborators of Katherine A. Rybinski based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Katherine A. Rybinski. Katherine A. Rybinski is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Nesic, Ksenija, Katherine A. Rybinski, Gwo‐Yaw Ho, et al.. (2025). Farletuzumab ecteribulin and MORAb‐109, folate receptor alpha and mesothelin targeting antibody–drug conjugates, show activity in poor prognosis gynaecological cancer models. Clinical and Translational Medicine. 15(3). e70274–e70274. 1 indexed citations
2.
Vandenberg, Cassandra J., Katherine A. Rybinski, Ksenija Nesic, et al.. (2023). Preclinical testing of farletuzumab ecteribulin (FZEC [MORAb-202]) and MORAb-109, folate receptor α and mesothelin targeting antibody-drug conjugates (ADCs), in rare gynecologic cancers.. Journal of Clinical Oncology. 41(16_suppl). e17634–e17634. 1 indexed citations
3.
4.
Furuuchi, Keiji, Katherine A. Rybinski, Tomoyuki Moriyama, et al.. (2022). Abstract P5-08-02: MORAb-202, an antibody-drug-conjugate (ADC) targeting folate receptor alpha (FRα), exhibits durable anti-tumor efficacy in PDx models of TNBC. Cancer Research. 82(4_Supplement). P5–8. 1 indexed citations
5.
Cheng, Xin, Jing Li, Keigo Tanaka, et al.. (2018). MORAb-202, an Antibody–Drug Conjugate Utilizing Humanized Anti-human FRα Farletuzumab and the Microtubule-targeting Agent Eribulin, has Potent Antitumor Activity. Molecular Cancer Therapeutics. 17(12). 2665–2675. 75 indexed citations
6.
Rybinski, Katherine A., Xin Cheng, Earl F. Albone, et al.. (2018). Abstract B115: MORAb-202: a folate receptor alpha (FRA)-targeting antibody-drug conjugate, exhibiting targeted antitumor activity and bystander elimination of cancer-associated fibroblasts. Molecular Cancer Therapeutics. 17(1_Supplement). B115–B115. 1 indexed citations
7.
8.
Rybinski, Katherine A., et al.. (2018). Abstract 1770: Morab-202, a folate receptor alpha-targeted antibody-drug conjugate, shows a highly potent activity against a panel of FRA-expressing tumors. Cancer Research. 78(13_Supplement). 1770–1770. 1 indexed citations
9.
Hekman, Marlène C.H., Otto C. Boerman, Desirée L. Bos, et al.. (2017). Improved Intraoperative Detection of Ovarian Cancer by Folate Receptor Alpha Targeted Dual-Modality Imaging. Molecular Pharmaceutics. 14(10). 3457–3463. 35 indexed citations
10.
Rybinski, Katherine A., Hongxia Z. Imtiyaz, James Fulmer, et al.. (2015). Targeting endosialin/CD248 through antibody-mediated internalization results in impaired pericyte maturation and dysfunctional tumor microvasculature. Oncotarget. 6(28). 25429–25440. 32 indexed citations
11.
Lin, Jianmin, Jared Spidel, Katherine A. Rybinski, et al.. (2013). The antitumor activity of the human FOLR1-specific monoclonal antibody, farletuzumab, in an ovarian cancer mouse model is mediated by antibody-dependent cellular cytotoxicity. Cancer Biology & Therapy. 14(11). 1032–1038. 43 indexed citations
12.
Tomkowicz, Brian, Katherine A. Rybinski, Philip M. Sass, et al.. (2010). Endosialin/TEM-1/CD248 regulates pericyte proliferation through PDGF receptor signaling. Cancer Biology & Therapy. 9(11). 908–915. 68 indexed citations
13.
Al‐Saleem, Fetweh H., et al.. (2008). A Natural Human IgM Antibody that Neutralizes Botulinum Neurotoxin in vivo. Hybridoma. 27(2). 65–69. 8 indexed citations
14.
Tomkowicz, Brian, Katherine A. Rybinski, Brian Foley, et al.. (2007). Interaction of endosialin/TEM1 with extracellular matrix proteins mediates cell adhesion and migration. Proceedings of the National Academy of Sciences. 104(46). 17965–17970. 117 indexed citations
15.
Hastie, Annette T., Min Wu, Gregory A. Hawkins, et al.. (2006). Alterations in vasodilator-stimulated phosphoprotein (VASP) phosphorylation: associations with asthmatic phenotype, airway inflammation and β2-agonist use. Respiratory Research. 7(1). 25–25. 7 indexed citations
16.
Pomorski, Lech, Jacek B. Cywiński, & Katherine A. Rybinski. (1996). Cancer in hyperthyroidism.. PubMed. 43(4). 217–9. 11 indexed citations
17.
Rybinski, Katherine A., et al.. (1989). Gastrin and Somatostatin Levels in Patients with Gastric Cancer. Hormone and Metabolic Research. 21(2). 89–91. 2 indexed citations
18.
Stępień, H, et al.. (1989). Elevated blood serum levels of epidermal growth factor in some patients with gastric cancer.. PubMed. 40(4). 149–53. 5 indexed citations
19.
Rybinski, Katherine A., et al.. (1978). [Experimental studies on the reconstruction of thoracic segment of the trachea].. PubMed. 32(5). 501–8. 1 indexed citations
20.
Rybinski, Katherine A., et al.. (1970). [Preparatory work preceding the performance of heart transplantation: experimental, clinical and organizational].. PubMed. 42(2). 159–65. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Wendy Cooper Breakdown of academic impact, for papers by Bianca Sijmons Breakdown of academic impact, for papers by Cécile Rouleau Breakdown of academic impact, for papers by Christel Herzog Breakdown of academic impact, for papers by Terry Lipari Breakdown of academic impact, for papers by Z Zhu Breakdown of academic impact, for papers by Hilda Tsai Breakdown of academic impact, for papers by Khashayar Lessan Breakdown of academic impact, for papers by Akinao Haba Breakdown of academic impact, for papers by Joëlle d'Anjou
Rankless by CCL
2026